Effect of Long-Term Hormone Therapy on Telomere Length in Postmenopausal Women by 源��젙�샇 et al.
Yonsei Medical Journal
Vol. 46, No. 4, pp. 471 - 479, 2005
Yonsei Med J Vol. 46, No. 4, 2005
Telomeres undergo attrition with each cell division, and
telomere length is associated with age-related diseases and
mortality in the elderly. Estrogen can influence the attrition
of telomeres by diverse mechanisms. This is a retrospective
case control study that investigated the influence of long-term
hormone therapy (HT) on telomere length in postmenopausal
women. We recruited 130 postmenopausal women from 55 to
69 years of age for this study, and divided them into two
groups. The first group included 65 women who had been on
estrogen and progesterone therapy for more than five years
(HT group). The other group was composed of 65 women
matched in age to the HT group who had never had HT (non-
HT group). The relative ratios of telomere length of study
subjects to a reference DNA from a healthy young female
were measured using quantitative PCR. Plasma levels of lipid
profiles, total antioxidant status (TAS), C-reactive proteins
(CRP), fasting glucose levels, and estradiol levels were mea-
sured. Age at menopause, vitamin use, and exercise, alcohol,
and cigarette smoking histories were also assessed in a
questionnaire. Mean duration (± SD) of HT was 8.4 ± 2.3
years. Prevalence of vitamin use and regular exercise were
higher in the HT group than in the non-HT group (p<0.01).
Relative telomere length ratios in the HT group were signifi-
cantly greater than those in the non-HT group (p<0.01). HT
was significantly correlated with the relative telomere length
ratio in multivariate analysis when potential confounding
variables were controlled for (p<0.05). In conclusion, telo-
mere lengths were longer in postmenopausal women who had
a history of long-term HT than in postmenopausal women
without HT. Long-term HT in postmenopausal women may
alleviate telomere attrition.
Key Words: Telomere, estrogen, menopause, hormone ther-
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INTRODUCTION
Telomeres are repetitive structures of the se-
quence of bases (TTAGGG) that appear at the
ends of mammalian chromosomes,1 and which
contribute to the stability and function of chromo-
somes by preventing degradation and end-to-end
fusion. Because of end replication problems, telo-
meres undergo attrition in groups of 20-200 base
pairs for each cell division until the critical telo-
mere length is reached. When the critical length
is reached, cells eventually enter into replicative
senescence.2,3 In humans, the telomere appears to
be a major component of cell senescence and
aging.
4
Alteration of telomere biology is shown in
genetic disorders or syndromes of accelerated
aging.5-7 Telomere length is also associated with
cardiovascular aging in males,
8,9
the severity of
Alzheimer's disease,10 and the mortality of elderly
people older than 60 years.11
The rate of telomere attrition is modified by
gender12 and oxidative stress.13 At birth, telomere
length is the same in both men and women,14 but
by adulthood telomeres are longer in women than
in men.8,9 This discrepancy between genders is
probably caused by the effects of estrogen. It has
been suggested that estrogen can protect telo-
meres against reactive oxygen species (ROS) and
induced DNA damage. Estrogen can also stimu-
late telomerase directly or indirectly by stimu-
lating nitric oxide production.15,16 Based upon
these observations, it is hypothesized that estro-
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gen's positive effects on telomere attrition may
affect postmenopausal women treated with long-
term hormone therapy (HT).
The aim of this study was to investigate the
influence of long-term HT on telomere attrition.
The differences of telomere length in both post-
menopausal women taking HT for more than five
years and in postmenopausal women without a
history of HT were compared to determine the
effects of long-term HT.
MATERIALS AND METHODS
Study population
Study subjects were recruited using an adver-
tisement from the health promotion center in a
women's hospital in Seoul, South Korea. All sub-
jects signed an informed consent form approved
by the hospital's Ethical Committee.
Two groups of study subjects were created on
the basis of hormone therapy history: the HT
group and the age-matched, non-HT group. The
HT group was defined as postmenopausal women
ranging in age from 55 to 69 years old who had
been taking estrogen (0.625 mg of conjugated
equine estrogen or 2 mg of estradiol combined
with progesterone) for more than five years. The
non-HT group was defined as postmenopausal
women ages 55 to 69 years old who had not taken
hormone therapy after menopause.
Exclusion criteria were high blood pressure
(mean systolic blood pressure 150 mmHg or
mean diastolic blood pressure 95 mmHg after
two consecutive measurements), high fasting
blood glucose (>126 mg/dL), abnormal liver func-
tion test (AST >35 IU/L, or ALT >35 IU/L), and a
medical history of hysterectomy or other illness
(hypertension, diabetes mellitus, liver disease).
The questionnaire assessed the medical history
of the study subjects, and included illness, age at
menopause, duration of HT, and vitamin use, as
well as lifestyles such as exercise, alcohol inges-
tion, and cigarette smoking. Vitamin use was de-
fined as daily use of vitamin C, vitamin E, or a
multivitamin. Jogging, walking, swimming, cyc-
ling, dancing or participating in alternate forms of
exercise more than three times a week for at least
30 minutes defined the exercise criteria. Alcohol
ingestion was defined as the ingestion of alcohol
more than one time each week. Smoking was de-
fined by current cigarette smoking. Sixty-five post-
menopausal women having had HT and 65 age-
matched postmenopausal women with no history
of HT were eligible for participation in this study
after assessing the inclusion and exclusion criteria.
The mean duration of HT (± SD) was 8.4 ± 2.3
years.
Biochemical assays
Biochemical tests were performed on blood
samples collected after more than 12 hours of
fasting. Venous blood was drawn and centrifuged,
and then the serum was immediately frozen in a
refrigerator at -80 . Serum levels of blood glu-
cose, high-sensitivity C-reactive protein (hs-CRP),
total cholesterol, HDL-cholesterol, and triglyce-
rides were assayed by enzymatic techniques (Bayer,
Tarrytown, NY, USA) using an auto-analyzer
ADVIA 1650 (Bayer, Tarrytown, NY, USA). LDL-
cholesterol was calculated using a Friedewald
formular.17 Estradiol was assayed by electrochemi-
luminescence immunoassay using Elecsys 2010
(Roche, Indianapolis, IN, USA). Plasma total
antioxidant status (TAS) was measured using a kit
supplied by Randox Laboratories (Diamond,
Crumlin, UK) following the methods previously
described by Re et al.18
Quantitative PCR
Relative ratios of telomere repeat copy number
to single copy gene number (T/S ratio) in study
subjects was compared with a reference DNA
obtained from a healthy young female genes were
measured by quantitative PCR as previously de-
scribed by Cawthon,19 but with the newly revised
primer set designed by Cawthon. This new primer
set, which has equal Guanine and Cytosine (GC)
content and a higher annealing temperature than
other published primers, shows improved correla-
tion with the relative mean terminal restriction
fragment(TRF) lengths (r
2
=0.971 vs 0.794, unpub-
lished data by Cawthon RM). This study used β-
globin as a single copy gene because it enhanced
PCR efficiency and reproducibility better than
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36B4 did.
Whole blood samples were collected by veni-
puncture and stored in EDTA-containing tubes.
Genomic DNA was extracted from white blood
cells by phenol/chloroform extraction using a
standard protocol. All DNA samples were di-
luted to the same concentration (based on ab-
sorbance) and stored at -80 until time of use.
Real time PCR was performed using a Light
Cycler (Roche, Mannheim, Germany). The rate of
accumulation of amplified DNA was measured by
continuous monitoring of SYBR Green I (Mole-
cular Probes, Eugene, Oregon, USA) as fluorescent
dye. Quantitative values were obtained from the
threshold cycle value (CT) at which a signal in-
crease associated with exponential growth of PCR
products was detected using Light Cycler analysis
software. Twelve microliters of the genomic DNA
were used to obtain the quantitative PCR in a
final volume of 20 L. The concentrations of reμ -
agents for telomere PCRs were 20 mM Tris-HCl
pH 8.4, 50 mM KCl, 200 M each dNTP, 1%μ
DMSO, 2.5 mM DTT, 0.4×SYBR Green I, 0.08 U
Platinum Taq Polymerase (Invitrogen, Carlsbad,
California, USA), 1.5 mM MgCl2, and 300 nM of
each telomere primer. The concentrations of
reagents for β-globin PCRs were 20 mM Tris-HCl
pH 8.4, 50 mM KCl, 200 μM each dNTP, 1% DMSO,
2.5 mM DTT, 0.4×SYBR Green I, 0.05 U Platinum
Taq Polymerase, 3.5 mM MgCl2, 300 nM β-globin
primer 1, and 500 nM β-globin primer 2.
Telomere primer sequences were 5'-CGGTTTGT
TTGGGTTTGGGTTTGGGTTT-GGGTTTGGGTT-3'
and 5'-GGCTTGCCTTACCCTTACCCTTACCCTT
ACCCTTA-CCCT-3'. -globin primer sequencesβ
were 5'-GCTTCTGACACAACTGTGTTCACTAGC-3'
and 5'-CACCAACTTCATCCACGTTCACC-3'. The
thermal cycling conditions for both amplicons be-
gan with two-minute incubation at 94 to activate
the Platinum Taq DNA polymerase and denature
the DNA. For telomere PCRs, 30 cycles were con-
ducted for 15 sec at 95 and for one minute at
56 . Thirty-five cycles of 15 sec at 95 , 20 sec at
56 , and 20 sec at 72 were conducted for β-glo-
bin PCR. At the end of the amplification cycles,
a melting temperature analysis was performed
using a slow increase in temperature (0.1 /sec,
up to 95 ). Each sample was analyzed using dup-
licates, and mean values were used for the study.
For the inter-assay coefficient of variation (CV),
nine DNA samples with the same concentration
were tested on three different days: inter-assay
CV for telomere and -globin PCR were 1.5β ± 0.7%
and 1.3 ± 0.9%, respectively. Nine different allo-
cations for intra-assay CV were tested in triplicate
with one DNA sample in the same plate: intra-
assay CV for telomere and β-globin PCR were 1.0
± 0.7% and 1.0 ± 1.1%, respectively.
Calculation of relative T/ S ratio
In order to reduce the inter-assay variation, the
same number of HT and non HT DNA were
allocated with reference DNA in each plate. Then
the CT values of both telomere and β-globin were
measured using quantitative PCR in each plate,
and the T/S ratio and relative T/S ratio were
calculated as follows:
Total amount of telomere in a DNA sample=
2-CT (telomere)
Total amount of globulin in a DNA sampleβ
=2-CT (β-globin)
T/S ratio in a DNA sample={2 CT (telomere)/2CT (β-
globin)}-1=2-Δ CT
The relative T/S ratio is the T/S ratio of one
sample relative to the T/S ratio of a reference
gene from a healthy young female, and this ratio
was calculated as follows:
Relative T/S ratio of study subjects={2Δ CT (telo-
mere)/2Δ CT (reference gene)}-1=2-Δ CTΔ .
Mean value of CΔ T for a reference gene was
12.73 ± 0.50.
Agarose gel electrophoresis of the telomere PCR
product
After 30 cycles of telomere PCR, each 20 L ofμ
the amplified product was analyzed by electro-
phoresis using 4% metaphor agarose gels running
for one hr at 50 V in 45 mM tris borate and one
mM EDTA with ethidium bromide. Gels were
visualized under ultra-violet (UV) illumination.
The PCR products were observed as a smear
beginning with great intensity at 78 bp, which was
the shortest possible product size, and progres-
sively fading to background with larger products.
This has been previously described by Cawthon19
(Fig. 1).
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Statistical analysis
Data are expressed as means ± SD. Clinical
characteristics were compared between the HT
and the non-HT groups using t-tests for the
continuous variables and Pearson chi-squares ( 2)
for the categorical variables. CT value differences
were compared between the HT and the non-HT
groups using t-tests. Relative T/S ratios were
compared between the two groups using the
Wilcoxon rank sum test because the distributions
were skewed. Multivariate linear regression an-
alyses were performed to determine the associa-
tion of HT and log2 values of relative T/S ratios
(Δ CΔ T) after adjusting for potential confounding
factors. All data were analyzed using the statis-
tical program SAS 8.01 (SAS Institute, Cary, NC,
USA).
RESULTS
Clinical characteristics of study subjects
Clinical characteristics are shown in Table 1.
Mean ages of the study subjects were 60.1 ± 3.5
years for the HT group and 60.3 ± 4.4 years for
the non-HT group with no statistical difference.
No statistical differences were found between the
two groups with regards to age, age at meno-
pause, blood pressure, cholesterol, triglyceride,
LDL-cholesterol, TAS, and hs-CRP levels. Serum
fasting glucose levels were significantly higher in
the non-HT group than in the HT group (p <
0.0001), but HDL-cholesterol levels were notably
higher in the HT group than in the non-HT group
(p < 0.001). Mean (± SD) serum estradiol levels of
the HT group were 35.6 (± 35.5) pg/L, which
were significantly higher than those in the non-
HT group (p < 0.0001). Women who participated
in regular exercise or took daily vitamins were
better represented in the HT group (p < 0.01 and
p < 0.01, respectively) than in the non-HT group.
Comparison of relative T/ S ratios
CT values of telomere PCR in the HT group
were significantly lower than those in the non-HT
group (p < 0.05). That is, the HT group had a
greater amount of telomeres than the non-HT
group because the total amount of telomeres in a
DNA sample was approximately 2-CT (telomere). CΔ T
values. were calculated by subtracting the β
globulin (single copy gene) CT value from the
telomere CT value, which was also significantly
lower in the HT group than in the non-HT group
(p<0.01)(Table 2). The HT group had greater T/S
ratios than the non-HT group of postmenopausal
women because the T/S ratio in a DNA sample
was approximately {2
CT (telomere)
/2
CT ( -globin)β
}
-1
= 2
-Δ
CT
. Relative T/S ratios of study subjects to a
reference (a healthy young female) were greater in
the HT group than in the non-HT group (p < 0.01)
(Table 3). In other words, telomere lengths were
longer in the HT group than in the non-HT group
of postmenopausal women.
Because serum fasting glucose levels, HDL
cholesterol levels, and the prevalence of regular
exercise and daily vitamin use statistically differed
between the two groups, and also because several
potential confounding factors known to be related
to telomere length existed in this study, a multiple
Fig. 1. Agarose gel electrophoresis following telo-
mere PCR. Each 20 l aliquot of the PCR productμ
was loaded onto prepared 4% metaphor agarose
gels in 45 mM tris borate and 1 mM EDTA with
ethidium bromide. The gel was run at 50 V for one
hr and visualized and photographed under UV
illumination. Lanes 1 and 6, size marker; lane 2,
DNA without telomere primers; lane 3, telomere
primers without DNA; lanes 4 and 5, human DNA
with telomere primers. The bottom of the smear in
lanes 4 and 5 was estimated to contain a 78 bp
telomere product.
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linear regression analysis was performed. This
was done to determine the association of relative
T/S ratios and long-term estrogen replacement
after adjusting for potential confounding vari-
ables. Log2 values of study subjects' relative T/S
ratios (ΔΔ CT) were used in the analysis to ac-
count for the skewed distribution. Adjusted re-
gression coefficients for Log2 values of relative T/
Table 1. Clinical Characteristics of Study Subjects
Characteristics HT Group (N=65) non-HT Group (N=65) p-value
Age (yrs) 60.1 ± 3.5 60.3 ± 4.4 0.83
Age at menopause (yrs) 49.5 ± 4.0 50.1 ± 3.7 0.39
BMI (Kg/m2) 23.1 ± 2.4 24.3 ± 2.6 < 0.05
Systolic BP§ (mmHg) 124.3 ± 12.4 127.4 ± 12.5 0.17
Diastolic BP (mmHg) 73.6 ± 8.9 74.9 ± 7.9 0.37
Smoking N (%) 1 (1.54) 1 (1.54) 1.00
Alcohol N (%) 17 (13.1) 9 (6.92) 0.08
Exercise¶ N (%) 43 (33.1) 29 (22.3) < 0.01
Vitamin intake** N (%) 42 (32.3) 27 (20.1) < 0.01
Fasting blood glucose (mg/dl) 83.8 ± 10.7 95.8 ± 7.6 < 0.0001
Cholesterol (mg/dl) 195.0 ± 41.7 198.7 ± 26.0 0.55
Triglyceride (mg/dl) 111.4 ± 52.1 129.4 ± 70.5 0.10
HDL-cholesterol (mg/dl) 61.5 ± 13.4 51.8 ± 9.2 < 0.0001
LDL-cholesterol (mg/dl) 111.2 ± 38.6 121.0 ± 24.2 0.09
TAS (mmol/L) 1.33 ± 0.09 1.32 ± 0.10 0.65
Hs-CRP (mg/L) 0.17 ± 0.59 0.07 ± 0.15 0.19
Estradiol (pg/L) 35.6 ± 35.5 10.6 ± 7.1 < 0.0001
Data are shown as mean ± standard deviation or number (%).
p-values are calculated by t-test or 
2
.
Postmenopausal women with hormone therapy including estrogen (conjugated equine estrogen 0.625 mg or estradiol 2 mg) plus
progesterone for more than five years.
Postmenopausal women without hormone therapy after menopause.
§
Blood pressure.
Alcohol ingestion 1 time a week.
¶
Doing regular exercise three times a week.
**Daily use of more than one vitamin including vitamin C, vitamin E, or multivitamins.
Total plasma antioxidant status.
High sensitivity C-reactive protein.
Table 2. Quantitative PCR Threshold cycles* (CT) of Postmenopausal Women with or without HT
HT Group (N=65) non-HT Group (N=65) p-value
CT (telomere)
§ 23.6 ± 1.01 24.1 ± 1.17 < 0.05
CT ( globulin)β 31.5 ± 0.72 31.4 ± 0.66 0.41
CTΔ ¶ -7.92 ± 0.99 -7.40 ± 1.33 < 0.01
Data are shown as mean ± standard deviation.
p-values are calculated by t-test.
*PCR cycle numbers at which a statistically significant increase in the emission intensity of the reporter dye was first detected.
Hormone therapy with estrogen (conjugated equine estrogen 0.625 mg or estradiol 2mg) plus progesterone for more than five years.
Postmenopausal women without hormone therapy after menopause.
§
CT value of telomere.
CT value of globulin.β
¶
CΔ T={CT(telomere)-CT( globulin)}.β
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S ratios are described in Table 4. HT showed
significant correlation with relative T/S ratios ( =β
0.56 SE=0.27 p<0.05), and no significant interac-
tion was found between relative T/S ratios and
the other variables.
DISCUSSION
In the present study, we demonstrated that
telomere lengths were significantly higher in post-
menopausal women who had undergone long-
term hormone therapy than in women who had
never taken estrogen after menopause. This result
suggests that conventional doses of long-term
hormone therapy after menopause might have the
effect of attenuating telomere attrition. From a
broader perspective, long-term hormone therapy
may affect human health by influencing telomere
biology in a manner that had not been previously
explored. Recent reports have demonstrated the
association between telomere length and age
related diseases,
3,8-10
as well as mortality in the
elderly.11
There are several factors that regulate telomere
attrition. Cellular replication is the principal regu-
lator of telomere attrition due to the so-called end
replication problem. Telomerase counteracts telo-
Table 3. Relative Telomere Length Ratios* of Postmenopausal Women with and without HT
Wilcoxon scores HT Group (N=65) non-HT Group (N=65) p-value
Sum 4853.5 3661.5 <0.01
Expected 4257.5 4257.5
Mean 74.7 56.3
p-values are calculated by the Wilcoxon rank sum test because of the skewed distribution.
* Telomere length ratio (T/S ratio) of study subjects relative to the ratio of a reference gene (from a healthy young female).
Hormone therapy with estrogen (conjugated equine estrogen 0.625 mg or estradiol 2 mg) plus progesterone for more than five years.
Postmenopausal women without hormone therapy after menopause.
Table 4. Results from a Multiple Linear Regression Model* for the Relative Telomere Length Ratio and Dependent
Variables in Study Subjects
Variables Coefficient SE T value p-value
HT§ 0.57 0.27 -2.17 <0.05
Age -0.04 0.03 -1.48 0.15
Pulse pressure 0.01 0.01 0.68 0.45
Exercise¶ 0.15 0.21 0.70 0.49
Vitamin use** 0.37 0.21 1.72 0.09
HDL cholesterol 0.01 0.01 1.58 0.12
Fasting glucose 0.02 0.01 1.64 0.10
TAS 0.92 1.10 0.83 0.41
Hs-CRP -0.16 0.24 -0.60 0.50
* F value, 2.21; p<0.05, R
2
, 0.14.
Telomere length ratio (T/S ratio) of study subjects relative to the ratio of a reference gene (from a healthy young female), the log2
values of relative telomere length ratios ( CΔΔ T) were used as the relative telomere length ratios in this procedure because of skewed
distribution.
Standard error.
§
Hormone therapy with estrogen (conjugated equine estrogen 0.625 mg or estradiol 2 mg) plus progesterone for more than five years.
Calculated by {Systolic blood pressure diastolic blood pressure}.
¶Doing regular exercise 3 times per week.
**Use of one or more vitamin among vitamin C, vitamin E, or multivitamin.
Total plasma antioxidant status.
High-sensitivity C-reactive protein.
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mere erosion in this specific condition. Another
important factor contributing to telomere short-
ening is the oxidative stress. Telomeres are highly
sensitive to oxidative stress-mediated damage in
vitro. In fact, the telomere shortening rate in
human fibroblasts among different cultures varies
by more than 1 - 2 orders of magnitude depending
on the oxidative stress.20,21 The preferential accu-
mulation of oxidative damage causes single-
stranded breaks that result in telomere erosion by
mechanisms that are independent of the end
replication problem.21-23 Antioxidants aid in the
attenuation of telomere shortening.3,24 Considering
that estrogen and its derivatives are known to
have antioxidant properties via diverse mecha-
nisms,15 the antioxidant capacity of long- term HT
might modify the influence of ROS on the telo-
mere shortening rate.
However, we failed to find any significant dif-
ferences in the serum total antioxidant status
(TAS) level between the HT and the non-HT
group. Also, there was no significant correlation
between the TAS level and the relative T/S ratio.
This result was irrelevant because estrogen is
believed to influence telomere attrition primarily
by its antioxidant effects. This discrepancy raised
the possibility that serum levels of the total
antioxidant capacity in one point in time might
not necessarily indicate the oxidative damages of
DNA in vivo. DNA damage is not only caused by
oxidative stress but is itself regarded as the most
sensitive biological marker for oxidative stress.
Despite the status of high sensitivity, there are
studies which demonstrate that there is no asso-
ciation between the percentage of DNA damage
and serum levels of antioxidant capacity.25,26
Mendoza-Nunez26 proposed that low serum levels
of total antioxidants are not always indicative of
oxidative stress. Moreover, it would be compli-
cated to measure the full spectrum of estrogen's
antioxidant actions by conventional methods. This
is because of the diverse mechanisms through
which estrogen exerts an antioxidant effect,15 e.g.,
scavenging free radicals, inhibiting free radical
formation and stimulating free radical enzymes.
In addition to its antioxidant effect, estrogen has
been shown to stimulate telomerase in a vitro
study.
27
This mode of action is thought to be
mediated by posttranscriptional modification
through stimulation of the phosphoinositol 3-
Kinase/Akt pathway.28,29 Estrogen can also in-
fluence telomerase activation by stimulating NO,
which has been proven to activate telomerase in
the endothelial cell line in recent vitro studies.30,31
Because serum estrogen levels in the HT group
were significantly higher than in the non-HT
group, we could hypothesize that telomerase acti-
vation aided in the alleviation of telomere attrition
in the HT group. Further studies will be needed
to confirm this hypothesis.
The traditional method for measuring telomere
length in human DNA is to determine a mean
TRF length by Southern blot analysis. However,
this method is time consuming, requires a large
amount of DNA, and shows variability depending
upon the particular restriction enzyme used.
However, measurement of the relative telomere
length ratio by quantitative PCR is simple and
allows for the rapid processing of large numbers
of samples. In previous research, relative T/S
ratios determined using quantitative PCR were
found to correlate well with mean TRF lengths.11,19
Also, agarose gel electrophoresis demonstrated
that the approximate size of major PCR products
was 78 bp with new primer set, as was expected.
In this study, postmenopausal women having
had HT were more prone to take vitamins and to
exercise regularly, so they may have practiced
better health habits than women in the non-HT
group. Serum levels of fasting blood glucose and
HDL-cholesterol were significantly different
between the two groups. These factors might be
a source of bias, but estrogen use still showed a
significant correlation with the relative telomere
length ratio in linear regression models after
adjusting for these factors.
There are some limitations to this study. First,
the retrospective nature of our study design does
not permit us to confirm the effect of estrogen
replacement on changes in telomere attrition.
Prospective studies are needed to evaluate the
role that estrogen therapy may have on the alle-
viation of telomere attrition. Also, because telo-
mere length has been shown to vary considerably
among individuals in previous studies, the small
sample size in this study may not offset an enrol-
ling bias.
In conclusion, telomere lengths were longer in
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postmenopausal women who had taken HT than
in postmenopausal women without a history of
HT. This suggests that long-term hormone ther-
apy in postmenopausal women might have the
effect of alleviating telomere attrition. Further
studies are necessary to more clearly understand
the relationship between hormone therapy and
telomere attrition.
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